India, Nov. 5 -- Evotec SE (EVO), a drug discovery and development company, reported third-quarter and nine-month 2026 financial results, highlighting improved quarterly profitability, stronger commercial momentum in its Discovery and Preclinical Development business and progress in its Horizon transformation program. Shares rose 4.78%.
Third-Quarter 2026 Results
Group revenue totaled €164.9 million, compared with €163.9 million in the third quarter of 2025. Revenue was €164.2 million at constant exchange rates (CER).
Adjusted Group EBITDA improved to a loss of €1.6 million, compared with a loss of €15.0 million in the prior-year quarter, representing an 89.1% improvement. The improvement was primarily drive...